Dietary Interventions to Prevent High Fructose Diet-associated Worsening of Colitis and Colitis-associated Tumorigenesis in Mice

Ryohei Nishiguchi¹*, Srijani Basu¹*, Hannah A. Staab¹, Naotake Ito¹, Xi Kathy Zhou², Hanhan Wang², Taehoon Ha², Melanie Johncilla³, Rhonda K. Yantiss³, David C. Montrose⁴,⁵ and
Andrew J. Dannenberg¹

Departments of ¹Medicine, ²Population Health Sciences, ³Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY; ⁴Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY; ⁵Stony Brook Cancer Center, Stony Brook, NY

*These authors contributed equally to this study

Grant support: Career Development Award from the Crohn's and Colitis Foundation (D.C.M.), New York Crohn’s Foundation (D.C.M. & A.J.D.), The Jill Roberts IBD Research Fund in honor of Ellen J. Scherl, M.D. (A.J.D.) and Tokyo Clinical Surgical Association (R.N., N.I.).

Corresponding Author: Andrew J. Dannenberg, Department of Medicine, Weill Cornell Medicine, 525 East 68th St, Room E-803, New York, NY 10065. Phone: 646-962-2892; Fax: 646-962-0891; Email: ajdannen@med.cornell.edu

Disclosures: The authors have nothing to disclose.

Summary of main findings (40 words allowed): Switching from a high fructose diet to a control diet or treatment with psyllium fiber protected against the pro-colitic effects of dietary fructose. These interventions also suppressed high fructose diet-mediated increase in colitis-associated colorectal tumorigenesis.
Abstract

Diet is believed to be an important factor in the pathogenesis of Inflammatory Bowel Disease. High consumption of dietary fructose has been shown to exacerbate experimental colitis, an effect mediated through the gut microbiota. This study evaluated whether dietary alterations could attenuate the detrimental effects of a high fructose diet (HFrD) in experimental colitis. First, we determined whether the pro-colitic effects of a HFrD could be reversed by switching mice from a HFrD to a control diet. This diet change completely prevented HFrD-induced worsening of acute colitis, in association with a rapid normalization of the microbiota. Second, we tested the effects of dietary fiber, which demonstrated that psyllium was the most effective type of fiber for protecting against HFrD-induced worsening of acute colitis, compared to pectin, inulin or cellulose. In fact, supplemental psyllium nearly completely prevented the detrimental effects of the HFrD, an effect associated with a shift in the gut microbiota. We next determined whether the protective effects of these interventions could be extended to chronic colitis and colitis-associated tumorigenesis. Using the azoxymethane/dextran sodium sulfate model, we first demonstrated that HFrD feeding exacerbated chronic colitis and increased colitis-associated tumorigenesis. Using the same dietary changes tested in the acute colitis setting, we also showed that mice were protected from HFrD-mediated enhanced chronic colitis and tumorigenesis, upon either diet switching or psyllium supplementation. Taken together, these findings suggest that high consumption of fructose may enhance colon tumorigenesis associated with long-standing colitis, an effect that could be reduced by dietary alterations.
Introduction

The incidence of Inflammatory Bowel Diseases (IBD) has increased worldwide (1-3). Increased consumption of a western diet has been suggested to contribute to the rising incidence of IBD (4-6). In addition to being high in saturated fat and low in fiber, a western diet is enriched in fructose (7-9). This has led to the hypothesis that diets high in fructose could contribute to the rising incidence of IBD (10-12). In support of this possibility, we and others found that a high fructose diet (HFrD) exacerbated experimental colitis in several mouse models (13,14). Dietary fructose induced changes in the fecal microbiota, which included a loss of probiotic bacteria, were causally linked to the worsening of colitis (13). Among its effects, dietary fructose has been found to alter the integrity of the gut barrier (13-16).

A well-recognized complication of longstanding colitis is an increased risk of colorectal cancer (CRC) (17-21). The risk for IBD patients to develop CRC increases with the extent of colitis, severity of inflammation, and duration of disease (22-24). Repetitive tissue destruction and renewal along with oxidative damage can induce mutations and tumor initiation, predisposing to colitis associated CRC (19,25-27). Because a HFrD causes worse acute experimental colitis, it is reasonable to posit that excess dietary fructose would also exacerbate chronic colitis leading to an increase in colitis-associated colorectal tumors. Developing strategies to attenuate colitis and thereby reduce the risk of colitis-associated CRC represents a significant unmet need. Chemoprevention strategies utilizing anti-inflammatory agents, e.g., 5-aminosalicylates have been tested but the benefits remain uncertain (28-30). In a recent epidemiological study, a diet imbalance with high consumption of soft drinks and sugar and low consumption of vegetables was associated with increased risk of ulcerative colitis (31). The possibility that this reflected the ability of vegetable-derived fiber to protect against the harmful effects of fructose was considered. Consistent with this possibility, psyllium fiber was recently reported to suppress acute experimental colitis (32).

The current study tested the ability of two potentially practical dietary alterations to attenuate HFrD-mediated exacerbation of experimental colitis and colitis-associated tumorigenesis. We found that either switching from a HFrD to a fructose-free diet or providing supplemental psyllium fiber protected against the worsening of acute and chronic colitis caused by a HFrD. Additionally, these two approaches suppressed the enhanced inflammation-associated colorectal tumor development resulting from high fructose feeding. These findings suggest that altering dietary patterns in IBD patients could reduce disease severity and the risk of developing colorectal cancer.

Materials and methods

Diet composition and induction of acute experimental colitis

Mice were fed AIN-93G purified diet (control) containing a mixture of carbohydrates (64 kcal%) or a HFrD (based on AIN-93G) in which all carbohydrate content comes from fructose. These two diets contain cellulose (5% w/w) as a source of fiber. Additional HFrD diets that were tested contained different fibers including psyllium, pectin and inulin (5% w/w). The details of the composition of the different diets are shown in Supplementary Table 1.

To induce colitis, mice were administered 1% dextran sodium sulfate (DSS; MP Biochemical) in drinking water for 7 days. For comparisons of colitis severity during DSS administration, measurements including body weight, rectal bleeding and diarrhea were carried out as previously described (33). Briefly, diarrhea was assessed by measuring the softness or appearance of the stool on a scale from 0 to 3. Bleeding was determined by
detection of heme in stool using the Hemoccult Sensa test (Beckman Coulter, Brea, CA) or
evidence of gross bleeding on a scale from 0 to 3. At the end of the experimental period,
mice were euthanized and colons were excised, length measured then they were flushed
with ice-cold phosphate-buffered saline. Colons were then fixed in 10% formalin or 4%
paraformaldehyde for 4-6 hrs, Swiss-rolled, paraffin-embedded then sectioned. Sections
were stained with hematoxylin and eosin (H&E) to determine the severity of histological
injury, using a scoring system that was adapted from (34). All animal studies were approved
by the Institutional Animal Care and Use Committee of Weill Cornell Medicine.

**Chronic colitis and colitis-associated colorectal tumor model**

C57BL/6J mice were purchased from the Jackson Laboratory and administered a
single intraperitoneal injection of azoxymethane (AOM) (10-12.5 mg/kg; Sigma Aldrich) at 9
weeks of age. At 12 weeks of age, 1% DSS was administered in drinking water for 5 days
followed by regular drinking water for 14 days. This cycle was repeated twice using 0.5%
and 0.25% DSS for the second and third rounds, respectively. Measurements including body
weight, rectal bleeding and diarrhea were carried out after the initiation of DSS as described
above.

At the end of the experimental period, colons were excised and flushed with PBS and
fixed in 4% paraformaldehyde. Whole mounts were stained with methylene blue for gross
enumeration of tumors then Swiss-rolled, paraffin embedded, and subjected to histologic
analysis by a gastrointestinal pathologist, following H&E staining. Colon sections were
evaluated using pathology scores for chronic DSS-induced colitis models, as previously
described (35).

**16S rRNA analysis**

Feces were collected from individual mice by placing them into empty cages. Feces
were snap-frozen in liquid nitrogen and stored at -80°C until shipped. One fecal pellet per
mouse was shipped to Molecular Research LP (Shallowater, TX) for 16S rRNA profiling.
DNA extraction from feces was carried out using the Powersoil DNA Kit (Qiagen) per
manufacturer’s instructions. Following DNA extraction, the 16S rRNA gene V4 variable
region PCR primers 515/806 with barcode on the forward primer were used in a 30 cycle
PCR using the HotStarTaq Plus Master Mix Kit (Qiagen) under the following conditions:
94°C for 3 minutes, followed by 30-35 cycles of 94°C for 30 seconds, 53°C for 40 seconds
and 72°C for 1 minute, after which a final elongation step at 72°C for 5 minutes was
performed. Pooled samples were purified using calibrated Ampure XP beads and the pooled
and purified PCR product was used to prepare illumina DNA library. Sequencing was
performed using an Illumina HiSeq. Sequence data were processed using the MR DNA
analysis pipeline (Shallowater, TX). In summary, sequences were joined, dephased of
barcodes then sequences <150bp or with ambiguous base calls were removed. Sequences
were denoised, OTUs generated and chimeras removed. Operational taxonomic units
(OTUs) were defined by clustering at 3% divergence (97% similarity). Final OTUs were
taxonomically classified using BLASTn against a curated database derived from RDPII and
NCBI (www.ncbi.nlm.nih.gov, http://rdp.cme.msu.edu).

**Statistical analysis**

To evaluate differences in study endpoints including colon length, histologic score,
tumor number, and tumor size between two experimental groups, the non-parametric
Wilcoxon rank-sum test was used. The non-parametric Kruskal-Wallis test was used to
evaluate differences in the above endpoints across multiple groups. Differences between
groups of interest were further assessed using Wilcoxon rank-sum test. P-values were
adjusted for multiple comparisons by using the Bonferroni-Holm method. These endpoints
were summarized graphically using box-plots with default summary statistics in R (e.g. center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers). Differences in tumor incidence in mice between or across experimental groups were examined using the Fisher’s exact test. For relative mouse body weight and the occurrence of bleeding (score ≥1), severe bleeding (score ≥2), diarrhea (score ≥1) or severe diarrhea (score ≥2) measured over time, linear and generalized linear mixed effects model were used where appropriate. Contrasts for parameters of interest including the rate of change in weight and average proportion of mice with bleeding, severe bleeding, diarrhea or severe diarrhea were examined using simultaneous tests of general linear hypotheses. P-values were adjusted for multiple comparisons by controlling the experiment-wise error rate using the “single-step” implementation in the R multcomp package. All the above described analyses were carried out in R.

Results
Switching from a HFrD to a fructose-free control diet protects against the pro-colitic effects of dietary fructose

Given previous work demonstrating that feeding a HFrD for 1 week to mice worsens acute colitis (13), we first tested whether removing the fructose-containing diet after 1 week of consumption, could reverse these effects. This approach was employed to mimic a potential clinical scenario in which IBD patients remove excess fructose from their diet. To test this, mice were fed a control diet for 21 days (days -35 to -14 in Figure 1A), 14 days of which bedding was swapped between cages in order to homogenize the microbiota (days -28 to -14 in Figure 1A). Mice were then either continued on control diet or given HFrD for 7 days (days -14 to -7 in Figure 1A), after which, half of the mice given HFrD were switched back to control diet for an additional week while the remaining mice were continued on their original diets (days -7 to 0 in Figure 1A). All mice were then challenged with 1% DSS in drinking water for 7 days (days 0 to 7 in Figure 1A) to induce colitis while being continued on their respective diets, and colitis severity was assessed. As shown in Figure 1B-D, mice fed the HFrD manifested markedly worse colitis compared to mice fed the control diet. However, mice switched from HFrD to control diet were protected from the pro-colitic effects of the HFrD, as demonstrated by attenuated weight loss, lack of colonic shortening and reduced histological injury (Figure 1B-D). Given our recent report showing the importance of the microbiota in HFrD-induced worsening of colitis, we next tested whether microbial changes paralleled the diet-mediated changes in colitis severity (13). Hence, we carried out 16S rRNA analysis of feces from mice fed the control diet for 28 or 35 days (Control group on days -7 and 0 in Figure 1A), HFrD for 7 or 14 days (HFrD group on days -7 and 0 in Figure 1A) or HFrD for 7 days then switched to control diet for 7 days (HFrD→Control group on days -7 and 0 in Figure 1A). As expected, principal coordinate analysis showed a marked shift in microbial populations following 7 or 14 days of HFrD feeding (Figure 1E). Consistent with the improvement in colitis (Figure 1, B-D), the changes in the microbial population induced by HFrD were rapidly reversed by switching mice back to control diet for 7 days (Figure 1E). When examined at the species level, the HFrD led to profound changes in the microbiota including increased abundance of Akkermansia muciniphila (A. muciniphila) and decreased abundance of Lactobacillus johnsonii (L. johnsonii), species both suggested to be important in HFrD-induced worsening of colitis (13) (Figure 1F; Supplementary Table 2). Remarkably, when the mice were switched from a HFrD to a control diet, the changes in these populations and others were rapidly reversed, and mimicked what was found in mice
fed control diet during the entire experiment (Figure 1F; Supplementary Table 2). Taken together, these results demonstrate that removing fructose from the diet led to a rapid reversal of the pro-colitic effects of the HFrD, which were paralleled by normalization of the microbiota.

**Psyllium supplementation protects mice from HFrD-induced exacerbation of acute colitis**

The above results indicate that removing fructose from the diet can rapidly prevent the pro-colitic effects of a HFrD. However, given how ubiquitous fructose is in both processed foods and sugar sweetened beverages, eliminating fructose from the diet may not be practical for many IBD patients. With this in mind, we next tested whether using a dietary supplement, a potentially more practical approach, would have a similar protective effect. To this end, we tested the efficacy of three different types of fiber including inulin, pectin and psyllium as compared to standard diet containing cellulose as its fiber source, on acute colitis severity during HFrD feeding (Supplementary Table 1). Mice were fed these four isocaloric diets for 1 week and then challenged with 1% DSS in drinking water to induce colitis while being continued on their respective diets, and colitis severity was assessed. As shown in Supplementary Figure 1, diet containing psyllium as its fiber source was most effective at protecting against the pro-colitic effects of a HFrD. We next determined to what extent psyllium protects against the detrimental effects of a HFrD. To test this, all mice were fed a control diet for 21 days (days -28 to -7 in Figure 2A), 14 days of which bedding was swapped between cages in order to homogenize the gut microbiota. Mice were then either continued on control diet containing cellulose, given HFrD containing cellulose or HFrD containing psyllium for 7 days (days -7 to 0 in Figure 2A). All mice were then challenged with 1% DSS in drinking water for 7 days to induce colitis while being continued on their respective diets, and colitis severity was assessed (days 0 to 7 in Figure 2A). As shown in Figure 2B-F, psyllium supplementation strongly protected against DSS-induced colitis during HFrD feeding. To determine whether the protective effect of psyllium on colitis was associated with microbial changes, we carried out 16S rRNA analysis of the feces from mice prior to DSS administration (day 0 in Figure 2A). These data showed that although feeding a HFrD induced a shift in microbial species, supplementation with psyllium caused a distinct shift altogether (Figure 2G; Supplementary Table 3).

**A HFrD exacerbates chronic colitis and increases colitis-associated colorectal tumor burden**

The above findings provide two potential methods to attenuate acute colitis enhanced by high fructose feeding. Therefore, we next sought to test whether these interventions protect against chronic colitis and the tumorigenesis associated with this condition. This concept is especially relevant given the increased risk of developing colon cancer in patients with long-standing IBD (17-21). Before evaluating these approaches in this setting, we first determined whether long-term administration of a HFrD would exacerbate chronic colitis and result in more colorectal tumors. To test this, the two isocaloric diets that were used in the acute studies described above were utilized: control diet (AIN-93G purified diet) containing a mixture of carbohydrates and a HFrD in which all carbohydrate content comes from fructose (Supplementary Table 1). As shown in Figure 3A, mice were fed the control diet for 21 days. Mice were then given one intraperitoneal injection of the colon carcinogen AOM (day 0 in Figure 3A). 14 days after receiving AOM, the mice were either continued on control diet or given HFrD for 7 days (days 14 to 21 in Figure 3A). The mice then received 3 rounds of decreasing concentrations of DSS (1 round = 5 days of DSS followed by 14 days of regular drinking water to induce colitis) (Figure 3A). Mice were given regular drinking water after the
last round until sacrifice (Figure 3A). Colitis severity (body weight, diarrhea) was assessed both during the experimental period and at the end of the study (colon length, histologic score). As shown in Figure 3B-E, each of these endpoints revealed that mice fed a HFrD manifested worse chronic colitis compared to mice fed the control diet.

To evaluate whether the exacerbation of chronic colitis mediated by a HFrD was associated with a greater colorectal tumor burden, colons were harvested at the end of the experimental period (day 92 in Figure 3A). Methylene blue staining of harvested colons and subsequent H&E staining of colonic sections suggested more tumors in the mice fed the HFrD (Figure 4A (a&b)). Direct counting of tumors on methylene blue-stained whole mounts revealed a significant increase in tumor incidence, number per mouse and size (Figure 4B-D). The differences in tumor number between groups were confirmed by counting tumors using H&E-stained sections of colons (0.17 ± 0.58 vs. 1.0 ± 1.21; P = 0.02). Taken together, these findings demonstrate that feeding a HFrD to mice enhances chronic colitis and the development of colitis-associated tumors.

Switching back to a control diet after HFrD feeding attenuates chronic colitis and tumor development

Having established that feeding a HFrD enhances chronic colitis and colitis-associated tumorigenesis (Figures 3 and 4) and switching from a HFrD to a control diet abrogates the acute pro-colitic effects of a HFrD (Figure 1), we next investigated whether dietary fructose removal attenuates chronic colitis and associated tumorigenesis. To test this, mice were first fed control diet for 21 days then administered AOM (Figure 5A). 14 days after receiving AOM (day 0 in Figure 5A), the mice were either continued on control diet or given HFrD for 7 days (days 14 to 21 in Figure 5A). 1% DSS was then given for 5 days to induce colitis followed by 7 days of regular drinking water (days 21 to 33 in Figure 5A). Half of the mice given HFrD diet were then switched back to a control diet (day 33 in Figure 5A) while the other half continued to receive the HFrD for the remainder of the study. Mice were continued on regular drinking water for an additional 7 days (days 33 to 40 in Figure 5A) then given two more rounds of DSS while being kept on their respective diets and colitis severity was evaluated. This design was intended to mimic the clinical scenario in which a patient with colitis might discontinue fructose consumption after having active disease for a period of time. As shown in Figure 5B-F, while mice given HFrD for the entire period manifested worse chronic colitis, those mice switched from a HFrD to a control diet after 1 round of DSS exposure developed less severe chronic colitis than mice that were maintained on the HFrD during the entire experimental period. In line with this amelioration of chronic colitis, switching from the HFrD to the control diet also attenuated the inflammation-associated pro-tumorigenic effect of high fructose feeding, including reductions in tumor incidence, number and size (Figure 5G-I).

Supplementation with psyllium attenuates chronic colitis and colitis-associated tumor burden in mice fed a HFrD

Given the marked ability of psyllium to attenuate HFrD-induced worsening of acute colitis (Figure 2), we next tested whether this agent can reduce chronic colitis and protect against colitis-associated tumorigenesis. Mice were fed control diet for 21 days then administered AOM (days -21 to 0 in Figure 6A). 14 days after receiving AOM (day 0 in Figure 6A), the mice were either continued on control diet or given HFrD for 7 days (days 14 to 21 in Figure 6A). 1% DSS was then given for 5 days to induce colitis followed by 7 days of regular drinking water (days 21 to 33 in Figure 6A). Half of the mice given HFrD diet were then given HFrD containing psyllium instead of cellulose (day 33 in Figure 6A) while the other half continued to receive the HFrD for the remainder of the study. Mice were continued
on regular drinking water for an additional 7 days (days 33 to 40 in Figure 6A) then given two more rounds of DSS while being kept on their respective diets. Measurements of colitis severity were carried out which showed that psyllium supplementation of the HFrD attenuated colitis severity (Figure 6B-F). Consistent with its ability to suppress chronic colitis in HFrD-fed mice, supplementary psyllium also reduced colon tumor incidence, number and size (Figure 6G-I).

Discussion
Fructose consumption has increased in association with rising rates of IBD (1, 2, 36, 37). Murine studies have shown a direct connection between high dietary fructose intake and worsening of colitis, including a role for gut microbiota in mediating this effect (13, 14). The current study demonstrates that dietary alterations including removal of fructose from diet following HFrD feeding as well as feeding supplemental psyllium, attenuate acute colitis. Moreover, high fructose feeding enhanced chronic colitis and increased colitis-associated tumor development, effects that were attenuated by either switching back to a control diet or feeding psyllium. Taken together, our findings suggest that high dietary fructose consumption may be a risk factor for tumor development in IBD patients, a potential risk factor that could be abrogated by dietary alterations.

The current study demonstrates that the detrimental effects of high fructose feeding on colitis severity are completely reversed by switching mice back to a control diet (Figure 1B-D). Interestingly, this protection occurred in parallel with a normalization of HFrD-induced shifts in gut microbial populations (Figure 1E & F). These findings suggest that reversal of fructose-induced microbial changes is key to the protection afforded by dietary fructose removal. In an initial study demonstrating that feeding a diet high in fructose exacerbated experimental colitis, alterations in microbial populations were also observed (14). A recent report by our group showed that high fructose feeding induced bacterial alterations but further found through bacterial ablation experiments that these microbial changes were responsible for the worsening of colitis (13). Moreover, we showed abundance, localization and metabolic changes in specific bacterial species that were likely contributors to the observed phenotype (13). Many of the species that changed in abundance as a result of HFrD feeding in this previous study, also changed in the same direction in the current work, including reduced Lactobacillus johnsonii and increased Akkermansia muciniphila (Figure 1F & Supplementary Table 2). Impressively, when mice were switched back to a control diet, both of these microbes reverted back to near their levels while on control diet (Figure 1F & Supplementary Table 2). The observed normalization in the abundance of these species might be especially important for the protection afforded by dietary fructose removal given their roles in deconjugation of bile acids (L johnsonii) and degradation of colonic mucus (A muciniphila) (38-40). Importantly, the overall findings of these experiments suggest that if dietary fructose worsens colitis in humans, altering the diet patterns of patients could be an effective preventive approach.

Given that changing patient behavior, including diet, can be challenging and the fact that fructose is abundant in processed foods and sugar sweetened beverages (36, 37, 41), intervention with a supplement might have greater utility to attenuate the detrimental effects of dietary fructose. To this end, we found that supplementation of the HFrD with psyllium markedly attenuated fructose-induced worsening of colitis (Figure 2A-F). Psyllium has previously been reported to be a key dietary factor that attenuates experimental colitis (32).
This protective effect was observed in both DSS-induced and T cell transfer models of colitis (32). The protection afforded by psyllium in this previous study appeared to be at least in part, microbiota-mediated (32). In line with these findings, our work suggests a role for the microbiota in psyllium-mediated protection against HFrD-induced exacerbation of colitis, given that psyllium feeding resulted in a unique shift in fecal bacterial populations (Figure 2G & Supplementary Table 3). In addition to this distinct pattern overall, examination at the species level revealed particular changes that might be related to the protection afforded by supplemental psyllium. For instance, *A. muciniphila* increased in abundance in HFrD fed mice, an effect that was attenuated when diet was supplemented with psyllium. This species is known to degrade colonic mucus and impair gut barrier function (13,39,42). A similar normalization in abundance was observed for *Bacteroides acidifaciens*, a microbe previously associated with experimental colitis (43,44). Whether microbial products derived from utilization of fiber could be playing a role in the protective effect of psyllium, warrants further investigation.

It is well-appreciated that chronic inflammation is a risk factor for developing neoplasia, especially in the GI tract (17-21). In fact, individuals with long-standing IBD are at increased risk for developing CRC (17-21). In light of the recent work reported by our group and others showing that feeding a HFrD to mice exacerbates acute experimental colitis, it stands to reason that this diet could also enhance chronic colitis and consequences thereof (13,14,17,18). In fact, the current work demonstrates that HFrD feeding worsens experimental chronic colitis which predisposes mice to colorectal tumor development. If elevated fructose consumption in humans worsens IBD severity, it is possible that such a diet could increase the risk of developing IBD-related cancer. Although it is likely that fructose-related worsening of inflammation is the mechanism by which greater tumor development occurs in mice, it is possible that direct utilization of fructose by colon tumors could enhance their development and growth (45). In order to test whether increased colon tumor burden resulting from HFrD feeding could be abrogated through intervention, the effects of dietary fructose removal and psyllium supplementation were tested. Impressively, both of these approaches markedly reduced tumor development under these conditions. Of note, each of these interventions was initiated after an initial DSS exposure while on HFrD diet. This scenario could be envisioned for IBD patients who have experienced flares while consuming a potentially harmful diet and elect to alter their dietary patterns to reduce their risk of developing colon cancer.
Legends to Figures

Figure 1. Switching from a HFrD to a control fructose-free diet protects against HFrD-induced worsening of colitis in association with normalizing the gut microbiota.
A. Experimental design showing groups and treatments of mice given control, HFrD or switched from HFrD to control diet. B-D, Measurements of colitis severity were carried out in mice described in Panel A during and following DSS exposure including body weight determined by calculating percent change on a given day compared to the weight on day 0 (according to Panel A) during DSS exposure (B), colon length measured following harvesting of colon at necropsy (C) and histologic score evaluated on H&E-stained sections of the colon (D) (n=7-8/group for panels B-D). *P<0.05, ***P<0.001. For C and D, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box. E and F, Fecal samples were collected from individual mice in each group on days -14, -7 and 0 (according to Panel A) and one pellet was used for 16S rRNA profiling. Data are shown by principal coordinate analysis (E) and the percent abundance of different bacteria in each group (F) (n=6/group for panels E&F). Black circle in Panel E indicates clustering of samples from the HFrD group on days -7 and 0 and the HFrD→Ctrl group on day -7.

Figure 2. Psyllium protects against HFrD-induced worsening of experimental colitis.
A. Experimental design showing groups and treatments of mice given control, HFrD or HFrD supplemented with psyllium. B-F, Measurements of colitis severity were carried out in mice described in Panel A during and following DSS exposure including body weight determined by calculating percent change on a given day compared to the weight on day 0 (according to Panel A) during DSS exposure (B), percent of mice with severe diarrhea as defined by having a score of ≥2 determined by assessing softness of stool (C), percent of mice with severe bleeding as defined by having a score of ≥2 determined by presence of blood in stool (D), colon length measured following harvesting of colon at necropsy (E) and histologic score evaluated on H&E-stained sections of the colon (F) (n=12-16/group for panels B-F). **P<0.01, ***P<0.001. For E and F, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers. (G) Microbial abundance in feces collected on day 0 (according to Panel A) is shown by principal coordinate analysis (n=6/group for panel G). Black circle indicates clustering of samples from mice fed HFrD containing psyllium.

Figure 3. HFrD feeding increases the severity of chronic colitis.
A. Experimental design showing groups and treatments of mice given control or HFrD. B-E, Measurements of colitis severity were carried out in mice described in Panel A during and following DSS exposure including body weight determined by calculating percent change on a given day compared to the weight on day 21 (according to Panel A) (B), percent of mice with diarrhea as defined by having a score >0 determined by assessing softness of stool (C), colon length measured following harvesting of colon at necropsy (D) and histologic score evaluated on H&E-stained sections of the colon (E) (n=12-16/group for panels B-E). For D and E, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers.

Figure 4. Feeding a HFrD increases colitis-associated tumorigenesis.
A. At the end of the study described in Figure 3A, tumor burden was assessed in mice using methylene blue staining on whole mount colons (a) and H&E staining on colonic sections (b) (20X). Arrowheads indicate tumors in a. Dashed line indicates tumor in b. (B-D) Tumor incidence (B), number per mouse (C) and size (D) were quantified in mice given control or HFrD at the end of the study described in Figure 3 (n=12-16/group for panels B-D). For C and D, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers.

**Figure 5. Switching to a control diet attenuates HFrD-mediated enhancement of chronic colitis and colitis-associated tumorigenesis.** A. Experimental design showing groups and treatments of mice given control, HFrD or switched from HFrD to control diet. B-F, Measurements of colitis severity were carried out in mice described in Panel A during and following DSS exposure including body weight determined by calculating percent change on a given day compared to the weight on day 21 (according to Panel A) (B), percent of mice with diarrhea as defined by having a score >0 determined by assessing softness of stool (C) percent of mice with bleeding as defined by having a score >0 determined by presence of blood in stool (D), colon length measured following harvesting of colon at necropsy (E) and histologic score evaluated on H&E-stained sections of the colon (F) (n=10/group for panels B-F). (G-I) Tumor incidence (G), number per mouse (H) and size (I) were quantified at the end of the experimental period shown in Panel A (n=17-19/group for panels G-I). *P<0.05, **P<0.01, ***P<0.001. NS = not significant. For E, F, H and I, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers.

**Figure 6. Psyllium supplementation protects against HFrD-induced worsening of chronic colitis and enhanced tumor development.** A. Experimental design showing groups and treatments of mice given control, HFrD or HFrD supplemented with psyllium. B-F, Measurements of colitis severity were carried out in mice described in Panel A during and following DSS exposure including body weight determined by calculating percent change on a given day compared to the weight on day 21 (according to Panel A) (B), percent of mice with diarrhea as defined by having a score >0 determined by assessing softness of stool (C), percent of mice with bleeding as defined by having a score >0 determined by presence of blood in stool (D), colon length measured following harvesting of colon at necropsy (E) (n=12-16/group for panels B-E) and histologic score evaluated on H&E-stained sections of the colon (F) (n=8/group for panel F). (G-I) Tumor incidence (G), number per mouse (H) and size (I) were quantified at the end of the experimental period (n=14-16/group for panels G-I). *P<0.05, **P<0.01, ***P<0.001. For E, F, H and I, components of box and whisker plots include: center line, median; box limits, upper and lower quartiles; whiskers, the most extreme data points within 1.5x interquartile range from the box; points, data points lying beyond the extremes of the whiskers.
References
1. Molodecky, N.A., et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*, 142, 46-54 e42; quiz e30.
2. Kaplan, G.G., et al. (2017) Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology*, 152, 313-321 e2.
3. (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *The lancet. Gastroenterology & hepatology*, 5, 17-30.
4. Rizzello, F., et al. (2019) Implications of the Westernized Diet in the Onset and Progression of IBD. *Nutrients*, 11.
5. Persson, P.G., et al. (1992) Diet and inflammatory bowel disease: a case-control study. *Epidemiology*, 3, 47-52.
6. Abegunde, A.T., et al. (2016) Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. *World journal of gastroenterology*, 22, 6296-317.
7. Cordain, L., et al. (2005) Origins and evolution of the Western diet: health implications for the 21st century. *The American journal of clinical nutrition*, 81, 341-54.
8. Kopp, W. (2019) How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases. *Diabetes, metabolic syndrome and obesity : targets and therapy*, 12, 2221-2236.
9. Lambertz, J., et al. (2017) Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease. *Frontiers in immunology*, 8, 1159.
10. Uranga, J.A., et al. (2016) Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. *Pharmacological reports : PR*, 68, 816-26.
11. Schreiner, P., et al. (2020) Nutrition in Inflammatory Bowel Disease. *Digestion*, 101 Suppl 1, 120-135.
12. Khalili, H., et al. (2018) The role of diet in the aetiopathogenesis of inflammatory bowel disease. *Nature reviews. Gastroenterology & hepatology*, 15, 525-535.
13. Montrose, D.C., et al. (2020) Dietary Fructose Alters the Composition, Localization and Metabolism of Gut Microbiota in Association with Worsening Colitis. *Cellular and molecular gastroenterology and hepatology*.
14. Kawabata, K., et al. (2019) A highfructose diet induces epithelial barrier dysfunction and exacerbates the severity of dextran sulfate sodiuminduced colitis. *International journal of molecular medicine*, 43, 1487-1496.
15. Sellmann, C., et al. (2015) Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. *The Journal of nutritional biochemistry*, 26, 1183-92.
16. Cho, Y.E., et al. (2019) Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. *Hepatology*.
17. Ekbom, A., et al. (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. *Lancet*, 336, 357-9.
18. Eaden, J.A., et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut*, 48, 526-35.
19. Itzkowitz, S.H., et al. (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *American journal of physiology. Gastrointestinal and liver physiology*, 287, G7-17.

20. Jess, T., et al. (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association*, 10, 639-45.

21. Rutter, M., et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology*, 126, 451-9.

22. Kim, E.R., et al. (2014) Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. *World journal of gastroenterology*, 20, 9872-81.

23. Canavan, C., et al. (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. *Alimentary pharmacology & therapeutics*, 23, 1097-104.

24. Lakatos, P.L., et al. (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. *World journal of gastroenterology*, 14, 3937-47.

25. Pereira, C., et al. (2015) Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. *Inflammatory bowel diseases*, 21, 2403-17.

26. Clevers, H. (2004) At the crossroads of inflammation and cancer. *Cell*, 118, 671-4.

27. Terzic, J., et al. (2010) Inflammation and colon cancer. *Gastroenterology*, 138, 2101-2114 e5.

28. Bernstein, C.N., et al. (2011) 5-aminosalicylate is not chemoprephylactic for colorectal cancer in IBD: a population based study. *The American journal of gastroenterology*, 106, 731-6.

29. Terdiman, J.P., et al. (2007) 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. *Inflammatory bowel diseases*, 13, 367-71.

30. Bernstein, C.N., et al. (2003) Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? *The American journal of gastroenterology*, 98, 2784-8.

31. Racine, A., et al. (2016) Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. *Inflammatory bowel diseases*, 22, 345-54.

32. Llewellyn, S.R., et al. (2018) Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. *Gastroenterology*, 154, 1037-1046 e2.

33. Montrose, D.C., et al. (2013) S1P(1) localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. *Journal of lipid research*, 54, 843-51.

34. O’Connor, W., Jr., et al. (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. *Nature immunology*, 10, 603-9.

35. Dieleman, L.A., et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. *Clinical and experimental immunology*, 114, 385-91.

36. Ogden, C.L., et al. (2011) Consumption of sugar drinks in the United States, 2005-2008. *NCHS data brief*, 1-8.

37. Bray, G.A. (2007) How bad is fructose? *The American journal of clinical nutrition*, 86, 895-6.

38. Ridlon, J.M., et al. (2006) Bile salt biotransformations by human intestinal bacteria. *Journal of lipid research*, 47, 241-59.

39. Ottman, N., et al. (2017) Genome-Scale Model and Omics Analysis of Metabolic Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading Lifestyle. *Applied and environmental microbiology*, 83.

40. Derrien, M., et al. (2011) Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. *Frontiers in microbiology*, 2, 166.

41. Bray, G.A. (2008) Fructose: should we worry? *International journal of obesity*, 32 Suppl 7, S127-31.
42. Seregin, S.S., et al. (2017) NLRP6 Protects Il10(-/-) Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. *Cell reports*, **19**, 733-745.

43. Alrafas, H.R., et al. (2019) Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. *Journal of leukocyte biology*, **106**, 467-480.

44. Berry, D., et al. (2015) Intestinal Microbiota Signatures Associated with Inflammation History in Mice Experiencing Recurring Colitis. *Frontiers in microbiology*, **6**, 1408.

45. Goncalves, M.D., et al. (2019) High-fructose corn syrup enhances intestinal tumor growth in mice. *Science*, **363**, 1345-1349.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6